Opko Health, Inc. revenue
Opko Health, Inc.'s revenue was $607m in fiscal 2025, down 14.9% on the year before. Since fiscal 2009 ($4.4m) it has grown at a compound 36.0% a year. Over the last twelve months it was $588m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 28 | 28 | 47 | 97 | 91 | 492 | 1,117 | 966 | 990 | 902 | 1,435 | 1,775 | 1,004 | 863 | 713 | 607 | 588 |
| Growth on the year before | — | +545.0% | −1.8% | +68.1% | +105.2% | −5.6% | +439.6% | +127.3% | −13.6% | +2.5% | −8.9% | +59.1% | +23.6% | −43.4% | −14.0% | −17.4% | −14.9% | — |
| Gross profit | 2 | 15 | 11 | 19 | 86 | 82 | 298 | 553 | — | — | — | — | — | 288 | 318 | 219 | 206 | 240 |
| Gross margin | 34.9% | 52.6% | 38.4% | 40.7% | 89.2% | 89.7% | 60.7% | 49.5% | — | — | — | — | — | 28.7% | 36.8% | 30.6% | 33.9% | 40.8% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Services | $370M | ▼ 23.0% |
| Products | $157M | ▲ 1.2% |
| Transfer of Intellectual Property and Other | $79.7M | ▲ 3.0% |
| Rayaldee | $59.4M | ▼ 14.3% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $436M | 71.9% | ▼ 20.2% |
| CL | $62.4M | 10.3% | ▼ 4.1% |
| Ireland | $51.4M | 8.5% | ▲ 6.2% |
| ES | $26.7M | 4.4% | ▲ 8.5% |
| Mexico | $25.5M | 4.2% | ▲ 6.9% |
| Other Countries | $4.3M | 0.7% | ▲ 36.8% |
| Israel | $522,000 | 0.1% | ▼ 70.5% |
From Opko Health, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Opko Health, Inc. | $588m | -11.5% | -12.2% |
| Alvotech | $586m | 19.7% | — |
| Emergent Biosolutions Inc. | $649m | -17.7% | -16.2% |
| Travere Therapeutics, Inc. | $651m | 49.4% | 71.3% |
| Amphastar Pharmaceuticals, Inc. | $730m | 1.0% | 10.5% |
| Pacira Biosciences, Inc. | $746m | 5.7% | 3.7% |
Compare with peers
- Alvotech revenue
- Emergent Biosolutions Inc. revenue
- Travere Therapeutics, Inc. revenue
- Amphastar Pharmaceuticals, Inc. revenue
- Pacira Biosciences, Inc. revenue
Head to head: ALVO vs OPKEBS vs OPKOPK vs TVTX
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies